|Bid||12.45 x 1300|
|Ask||13.55 x 800|
|Day's Range||12.43 - 13.48|
|52 Week Range||11.02 - 25.99|
|Beta (3Y Monthly)||2.25|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.00|
Added seven new partner-funded programs in 2018 with potential for milestone and royalty paymentsCurrent cash balance sufficient to fund operations for multiple years.
XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts. The presentation will take place on Tuesday, March 12, 2019, at 12:00PM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com. An archived version of the webcast will be available for 90 days after the event. XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs. XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future. For more information, visit www.xoma.com.
XOMA Corporation (XOMA) announced today it has received a $5.5 million payment from Rezolute, Inc., related to the Companies’ 2017 license agreement, as most recently amended on January 7, 2019. “Our business model is fundamentally designed to generate significant long-term royalty-based revenue as the underlying assets are commercialized. Moreover, many of our license agreements include the potential for XOMA to receive significant milestone payments as the licensed assets progress. The receipt of this milestone payment is a good example of XOMA further strengthening its balance sheet with additional non-dilutive capital. This capital can be deployed to further expand our portfolio of assets from which we have the potential to earn future milestone payments and royalties,” commented Jim Neal, Chief Executive Officer at XOMA.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We've lost count of how many times Read More...
EMERYVILLE, Calif., Jan. 03, 2019 -- XOMA Corporation (NASDAQ: XOMA) announced today Barbara Kosacz, a Partner at Cooley LLP, has joined the Company’s Board of Directors. Ms..
The Rights Offering was made pursuant to the Company’s effective shelf registration statement on file with the Securities and Exchange Commission (“SEC”) and a prospectus supplement and accompanying prospectus filed with the SEC on November 19, 2018. XOMA has engaged D.F. King & Co., Inc., to act as information agent with respect to the Rights Offering. For questions regarding the Rights Offering, or to obtain copies of the Rights Offering prospectus and any related materials, please contact D.F. King & Co. at firstname.lastname@example.org or by telephone at +1 866-721-1324.
Xoma (XOMA) delivered earnings and revenue surprises of -44.74% and 7.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Emeryville, California-based company said it had a loss of 55 cents. The drug developer posted revenue of $896,000 in the period. Xoma shares have declined 65 percent since the ...
EMERYVILLE, Calif., Nov. 07, 2018 -- XOMA Corporation (Nasdaq: XOMA), a biotechnology royalty aggregator, today announced its third quarter 2018 financial results. “The third.
Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the Gastrobiome™, today announced the appointments of James R. Neal and James Sapirstein to its board of directors. With more than three decades of life science industry experience each, Mr. Neal and Mr. Sapirstein provide Leading BioSciences with broad expertise in such areas as drug development and commercialization, strategic business operations, financial management and business development transactions. Mr. Neal, who currently serves as chief executive officer and board member for XOMA Corporation (XOMA), has nearly 35 years of life science industry leadership experience. His expertise spans such areas as development and commercialization of novel technologies and products, as well as formation and oversight of successful global business and technology collaborations. In his current role at XOMA, Mr. Neal spearheaded and secured the requisite capital to support a strategic transition of the company’s operations to focus on a royalty monetization model. Prior to XOMA, Mr. Neal served as acting chief executive officer of Entelos, Inc, a leader in bio-simulation technologies, at which he was responsible for partnerships with global pharmaceutical companies such as Eli Lilly and GlaxoSmithKline. He was chief executive officer at Iconix Biosciences at the time it was acquired by Entelos in 2007. While at Iconix, Mr. Neal was credited with establishing multi-year collaborations with Bristol-Myers Squibb, Abbott Labs, Eli Lilly and the U.S. Food and Drug Administration. He also previously served as executive vice president of Incyte Genomics, where he led the global commercial activities with pharmaceutical company collaborators and partners including Pfizer, Aventis and Schering-Plough, as well as sales, marketing and business development activities for the company.
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A look at the shareholders of XOMA Corporation (NASDAQ:XOMA) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insidersRead More...
Xoma (XOMA) delivered earnings and revenue surprises of -15.00% and -50.60%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Emeryville, California-based company said it had a loss of 23 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...